CA153、CA125、CEA联合检测在乳腺癌诊断和预后评估中的价值

摘要/Abstract

摘要： 目的评价血清糖类抗原153（CA153）、糖类抗原125（CA125）、癌胚抗原（CEA）联合检测在乳腺癌（BC）诊断和预后评估中的价值。方法收集2017年1月—2019年6月在烟台市莱阳中心医院初次诊疗的112例BC患者（乳腺癌组）及同期来医院诊疗的50例乳腺良性病变患者（良性对照组）的临床病历资料,两组均有血清CA153、CA125、CEA检查资料。结果乳腺癌组血清CA153、CA125、CEA水平高于良性对照组,差异有统计学意义（P<0.05）。血清CA153、CA125联合CEA诊断BC的敏感性、准确性、阴性预测值高于单独血清标志物诊断的敏感性、准确性、阴性预测值,差异有统计学意义（P<0.05）。BC血清CA153、CA125、CEA高水平表达组5年无事件发生率低于低水平表达组,差异有统计学意义（P<0.05）。结论 CA153、CA125联合CEA可提高BC的诊断价值,且三者高表达患者的远期预后更差。

关键词: 乳腺癌, 糖类抗原153, 糖类抗原125, 癌胚抗原, 诊断, 预后

Abstract: Objective To evaluate the value of combined detection of serum carbohydrate antigen 153 (CA153), carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) in the diagnosis and prognosis of breast cancer (BC). Methods The clinical case data of 112 BC patients (breast cancer group) who were initially treated in Yantai Laiyang Central Hospital from January 2017 to June 2019, and 50 patients with benign breast lesions (benign control group) who visited the hospital during the same period were collected.Serum CA153,CA125 and CEA were detected in both groups. Results The serum levels of CA153,CA125 and CEA in breast cancer group were higher than those in benign control group,and the difference was statistically significant(P<0.05).The sensitivity,accuracy and negative predictive value of serum CA153 and CA125 combined with CEA in the diagnosis of BC were higher than those of single serum markers, and the differences were statistically significant (P<0.05).The 5-year no-event incidence rate in the BC serum CA153, CA125, and CEA high-level expression group was lower than that of the low-level expression group, which was statistically significant (P<0.05). Conclusion CA153,CA125 combined with CEA can improve the diagnostic value of BC, and the long-term prognosis of patients with high expression of CA153 and CA125 is worse.

Key words: breast cancer, carbohydrate antigen 153, carbohydrate antigen 125, carcinoembryonic antigen, diagnosis, prognosis

中图分类号:

R737.9

李薇, 周武松. CA153、CA125、CEA联合检测在乳腺癌诊断和预后评估中的价值[J]. 中华养生保健, 2025, 43(10): 174-178.

LI Wei, ZHOU Wu-song. Value of CA153, CA125 and CEA Combined Tests in Diagnosis and Prognosis Assessment of Breast Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2025, 43(10): 174-178.

参考文献

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] KASHYAP D,PAL D,SHARMA R,et al.Global increase in breast cancer incidence:risk factors and preventive measures[J].Biomed Res Int,2022,18(2022):9605439.
[3] 刘磊,谢忠民.乳腺癌患者术后复发转移的危险因素及血清LDH、CA153 对复发转移的预测价值[J].吉林医学,2024,45(11):2694-2697.
[4] KATSURA C,OGUNMWONYI I,KANKAM H K,et al.Breast cancer:presentation,investigation and management[J].Br J Hosp Med (Lond),2022,83(2):1-7.
[5] NAEEM M,ZULFIQAR M,BALLARD D H,et al.“The unusual suspects”-mammographic,sonographic,and histopathologic appearance of atypical breast masses[J].Clin Imaging,2020,66:111-120.
[6] FANG Q,SHEN G,XIE Q,et al.Development of tumor markers for breast cancer immunotherapy[J].Curr Mol Med[J].2024,24(5):547-564.
[7] 吴世园,罗蔚,姚俐霞,等.血清癌胚抗原、糖类抗原125、糖类抗原153单独及联合检测对乳腺癌的诊断价值[J].癌症进展,2024,22(16):1802-1805.
[8] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609-679.
[9] 赵媛媛,王帅力,高晓莉.血清铁蛋白、癌胚抗原、糖类抗原15-3联合检测在乳腺癌诊断、复发转移预测中的价值分析[J].癌症进展,2022,20(9):956-958.
[10] 吴长蓉,唐熟能,叶红珍.乳腺肿瘤标志物联合检测在乳腺癌患者术后监测中的应用[J].检验医学与临床,2022,19(17):2323-2330.
[11] YAN S,YUE S.Identification of early diagnostic biomarkers for breast cancer through bioinformatics analysis[J].Medicine (Baltimore),2023,102(37):e35273.
[12] BLOCK J E,GENANT H K,BLACK D.Greater vertebral bone mineral mass in exercising young men[J].West J Med,1986,145(1):39-42.
[13] SCHECTER R L,MAJOR P P,KOVAC P E,et al.Double antibody radioimmunoassay for monitoring metastatic breast cancer[J].Br J Cancer,1988,58(3):362-367.
[14] TAINSKY M A.Genomic and proteomic biomarkers for cancer:a multitude of opportunities[J].Biochim Biophys Acta,2009,1796(2):176-193.
[15] 陈爽冉,岳玉桃,张芳,等.高频超声检查结合粗针穿刺活检在鉴别乳腺癌中的应用及其与血清CA125、CA153的相关性[J].实用癌症杂志,2022,37(2):315-318.
[16] KHUSHK M,KHAN A,REHMAN A,et al.The role of tumor markers:carcinoembryonic antigen and cancer antigen 15-3 in patients with breast cancer[J].Cureus,2021,13(7):e16298.
[17] PU Q,GAO H.The role of the tumor microenvironment in triple-positive breast cancer progression and therapeutic resistance[J].Cancers (Basel),2023,15(22):5493.
[18] ERFANI S,HUA H,PAN Y,et al.The context-dependent impact of integrin-associated CD151 and other tetraspanins on cancer development and progression:a class of versatile mediators of cellular function and signaling,tumorigenesis and metastasis[J].Cancers (Basel),2021,13(9):2005.
[19] 白云鹤,王阳,齐丽丽,等.乳腺癌患者手术前后CA153、SCC和HE4水平变化及复发预测分析[J].分子诊断与治疗杂志,2022,14(9):1570-1573.
[20] 田二军,王滨,姜楠.血清CYFRA21-1、CA125、CA153、CEA 对乳腺癌的诊断及预测术后复发的价值[J].河南医学研究,2024,33(11):2037-2040.
[21] 韩梅,马明杰,连俊,等.血清AFP、CEA、CA199、CA125、HE4联合检测在卵巢癌诊断中的应用价值[J].河北医药,2022,44(1):76-78,82.
[22] 杨英花,张梦婷,崔立春,等.3项肿瘤标志物在乳腺癌中的临床诊断价值[J].检验医学与临床,2023,20(21):3164-3167.
[23] 郭剑辉,王骞.Ⅰ~Ⅲ期浸润性乳腺癌患者治疗前血清肿瘤标志物与分子分型临床病理学特征的相关性研究[J].河北医学,2021,27(11):1782-1790.
[24] WANG W,XU X,TIAN B,et al.The diagnostic value of serum tumor markers CEA,CA19-9,CA125,CA15-3,and TPS in metastatic breast cancer[J].Clin Chim Acta,2017,470:51-55.
[25] 郑加荣,薄丽英,孔芹,等.乳头溢液肿瘤标志物癌胚抗原、糖类抗原 153、糖类抗原125联合检测在乳腺癌诊断中的价值[J].中医临床研究,2024,16(5):129-133.
[26] 吴琳,秦峰.ProGRP联合CEA和CA153在乳腺癌患者血清中的表达及其临床诊断价值[J].检验医学与临床,2021,18(23):3387-3390.
[27] 黄晓阳,陈阳,张露露,等.血清CEA、CA125表达与进展期乳腺癌临床病理特征及新辅助化疗效果的关系[J].实用癌症杂志,2024,39(9):1534-1539.
[28] 徐书星,霍庆赟,张明远,等.血清CA153、CEA、SF、CT及Hcy联合检测对乳腺癌的临床诊断价值[J].分子诊断与治疗杂志,2020,12(2):190-194.
[29] 陈琛,王征,郭满高,等.血清CA153、BXTM及CEA联合检测对乳腺癌的早期诊断价值比较[J].中国实验诊断学,2020,24(12):1978-1981.
[30] 任俞华,姜柯.血清CEA、CA125和CA153联合检测对乳腺癌患者的诊断价值[J].中国肿瘤临床与康复,2020,27(10):1196-1198.
[31] 任丽,柳雅慧,夏文超,等.乳腺癌细胞缺氧微环境中癌胚抗原的表达及其对预后的判断意义[J].中华检验医学杂志,2016,39(9):710-714.
[32] LUO G,HU N,XIA X,et al.RPN11 deubiquitinase promotes proliferation and migration of breast cancer cells[J].Mol Med Rep,2017,16(1):331-338.
[33] 傅静芬. 血清CEA、CA125、CA153联合HER2对乳腺癌的诊断价值[J].中国医学创新,2023,20(8):105-108.